Table 2.
Zinc content in dietary supplements [mg/capsule] and potential relative bioaccessibility [%].
| Code | Fraction | Average Content [mg/Capsule] (Range) |
Total Content a [mg] |
Potential Relative Bioaccessibility [%] |
Percentage of UL (for 1 Capsule/Tablet) b [%] |
|---|---|---|---|---|---|
| DS1 | A | 28.4 ± 4.90 (21.8–33.6) |
30.8 | 7.86 | 123 |
| B | 2.42 ± 0.008 (2.42–2.43) |
||||
| DS2 | A | 10.2 ± 1.11 (8.81–11.5) |
11.3 | 9.38 | 45.2 |
| B | 1.06 ± 0.24 (0.80–1.38) |
||||
| DS3 | A | 16.6 ± 1.64 (14.3–18.2) |
16.8 | 1.13 | 67.2 |
| B | 0.19 ± 0.12 (0.05–0.33) |
||||
| DS4 | A | 23.3 ± 2.29 (20.5–26.1) |
24.1 | 3.15 | 96.4 |
| B | 0.76 ± 0.05 (0.72–0.83) |
||||
| DS5 | A | 35.9 ± 10.8 (25.1–46.7) |
36.6 | 1.99 | 146 |
| B | 0.73 ± 0.01 (0.72–0.75) |
||||
| DS6 | A | 30.0 ± 0.67 (29.4–30.9) |
31.1 | 3.38 | 124 |
| B | 1.05 ± 0.003 (1.04–1.05) |
||||
| DS7 | A | 32.2 ± 4.03 (26.7–36.0) |
33.7 | 4.48 | 135 |
| B | 1.51 ± 0.002 (1.50–1.51) |
||||
| DS8 | A | 12.6 ± 1.09 (11.7–14.1) |
13.4 | 6.19 | 53.6 |
| B | 0.83 ± 0.13 (0.65–0.96) |
||||
| DS9 | A | 31.7 ± 0.77 (31.0–32.8) |
33.6 | 5.77 | 134 |
| B | 1.94 ± 0.10 (1.82–2.05) |
||||
| DS10 | A | 16.2 ± 0.71 (15.2–16.8) |
17.3 | 6.59 | 69.2 |
| B | 1.14 ± 0.13 (0.97–1.30) |
a Sum of fraction A and B. b EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. [32]; UL—tolerable upper intake level (25 mg/day for adults).